glp 1 for older adults Weighing the risk of GLP-1 treatment in adults: Should we be concerned about sarcopenic obesity? Older adults using GLP-1s should

And I really think that that was the big change in my perspective and the best evidence for this, and I cite two examples in the book, which I think are two of the largest examples, is when you contrast the effect of treating patients with metastatic cancer versus treating patients in the adjuvant setting for the same cancer with the same drug

More trials that report changes in fat mass, lean mass and cardiometabolic outcomes will clarify the actual health benefit of each approach beyond the scale number

Lipomas have homogeneous low attenuation on CT similar to subcutaneous or mediastinal fat, typically less than 50 Hounsfield units (Fig

Ethics declarations Conflict of interest The authors have filed the provisional Indian patent applications no: 202521056008 and 202521056068, which is part of this research work